** Shares of Iovance Biotherapeutics IOVA.O fall 8.1% to $3.76 premarket

** The drugmaker reports Q1 total revenue of $71.43 million, missing estimates of $78.40 million

** Says revenue was affected by maintenance of its Iovance cell therapy center

** Reports Q1 U.S. sales of its skin cancer drug Amtagvi of about $60 million, missing analysts estimates of $69.08 million

** Forecasts 2026 total product revenue to be in $350 million-$370 million; analysts on an average expected $370.48 million - data compiled by LSEG

** Iovance's cash position was about $319 million on March 31, 2026, expected to fund operations well into 2028- IOVA

** Up to last close, stock up 49.8% YTD